Genetics, Pathogenesis and Clinical Interventions in Type 1 Diabetes

Overview

Journal Nature

Specialty Science

Date 2010 May 1

PMID 20432533

Citations 536

Authors

Jeffrey A Bluestone

Kevan Herold

George Eisenbarth

Affiliations

Soon will be listed here.

Abstract

Type 1 diabetes is an autoimmune disorder afflicting millions of people worldwide. Once diagnosed, patients require lifelong insulin treatment and can experience numerous disease-associated complications. The last decade has seen tremendous advances in elucidating the causes and treatment of the disease based on extensive research both in rodent models of spontaneous diabetes and in humans. Integrating these advances has led to the recognition that the balance between regulatory and effector T cells determines disease risk, timing of disease activation, and disease tempo. Here we describe current progress, the challenges ahead and the new interventions that are being tested to address the unmet need for preventative or curative therapies.

Citing Articles

Infections and antibiotic use in early childhood have limited importance in developing manifest type 1 diabetes - The ABIS cohort study.

Belteky M, Wahlberg J, Ludvigsson J Front Endocrinol (Lausanne). 2025; 16:1529447.

PMID: 40060384 PMC: 11885132. DOI: 10.3389/fendo.2025.1529447.

The application of procyanidins in diabetes and its complications: a review of preclinical studies.

Zhang Y, Li M, Liu H, Fan Y, Liu H Front Pharmacol. 2025; 16:1532246.

PMID: 39995417 PMC: 11847907. DOI: 10.3389/fphar.2025.1532246.

Cellular therapies in rheumatic and musculoskeletal diseases.

Franco-Fuquen P, Figueroa-Aguirre J, Martinez D, Moreno-Cortes E, Garcia-Robledo J, Vargas-Cely F J Transl Autoimmun. 2025; 10:100264.

PMID: 39931050 PMC: 11808717. DOI: 10.1016/j.jtauto.2024.100264.

High-Yield Generation of Glucose-Responsive Pseudoislets From Murine Insulinoma Cells for Studies and Longitudinal Monitoring of Graft Survival .

Gonzalez G, Li C, Pasolini I, Pete S, Verheyen C, Vignolo S Cell Transplant. 2025; 34:9636897251315123.

PMID: 39881520 PMC: 11780636. DOI: 10.1177/09636897251315123.

Emerging Immunotherapies for Disease Modification of Type 1 Diabetes.

Foster T, Bruggeman B, Haller M Drugs. 2025; .

PMID: 39873914 DOI: 10.1007/s40265-025-02150-8.

References

Yan Z, Garg S, Kipnis J, Banerjee R . Extracellular redox modulation by regulatory T cells. Nat Chem Biol. 2009; 5(10):721-3. PMC: 2760945. DOI: 10.1038/nchembio.212. View

Esensten J, Lee M, Glimcher L, Bluestone J . T-bet-deficient NOD mice are protected from diabetes due to defects in both T cell and innate immune system function. J Immunol. 2009; 183(1):75-82. PMC: 2732575. DOI: 10.4049/jimmunol.0804154. View

Burton A, Vincent E, Arnold P, Lennon G, Smeltzer M, Li C . On the pathogenicity of autoantigen-specific T-cell receptors. Diabetes. 2008; 57(5):1321-30. DOI: 10.2337/db07-1129. View

Suarez-Pinzon W, Yan Y, Power R, Brand S, Rabinovitch A . Combination therapy with epidermal growth factor and gastrin increases beta-cell mass and reverses hyperglycemia in diabetic NOD mice. Diabetes. 2005; 54(9):2596-601. DOI: 10.2337/diabetes.54.9.2596. View

Feuerer M, Hill J, Mathis D, Benoist C . Foxp3+ regulatory T cells: differentiation, specification, subphenotypes. Nat Immunol. 2009; 10(7):689-95. DOI: 10.1038/ni.1760. View

Boni-Schnetzler M, Thorne J, Parnaud G, Marselli L, Ehses J, Kerr-Conte J . Increased interleukin (IL)-1beta messenger ribonucleic acid expression in beta -cells of individuals with type 2 diabetes and regulation of IL-1beta in human islets by glucose and autostimulation. J Clin Endocrinol Metab. 2008; 93(10):4065-74. PMC: 2579638. DOI: 10.1210/jc.2008-0396. View

Virtanen S, Kenward M, Erkkola M, Kautiainen S, Kronberg-Kippila C, Hakulinen T . Age at introduction of new foods and advanced beta cell autoimmunity in young children with HLA-conferred susceptibility to type 1 diabetes. Diabetologia. 2006; 49(7):1512-21. DOI: 10.1007/s00125-006-0236-1. View

Dotta F, Censini S, van Halteren A, Marselli L, Masini M, Dionisi S . Coxsackie B4 virus infection of beta cells and natural killer cell insulitis in recent-onset type 1 diabetic patients. Proc Natl Acad Sci U S A. 2007; 104(12):5115-20. PMC: 1829272. DOI: 10.1073/pnas.0700442104. View

Bougneres P, Carel J, Castano L, Boitard C, Gardin J, Landais P . Factors associated with early remission of type I diabetes in children treated with cyclosporine. N Engl J Med. 1988; 318(11):663-70. DOI: 10.1056/NEJM198803173181103. View

10.

Masteller E, Warner M, Tang Q, Tarbell K, McDevitt H, Bluestone J . Expansion of functional endogenous antigen-specific CD4+CD25+ regulatory T cells from nonobese diabetic mice. J Immunol. 2005; 175(5):3053-9. DOI: 10.4049/jimmunol.175.5.3053. View

11.

Feuerer M, Herrero L, Cipolletta D, Naaz A, Wong J, Nayer A . Lean, but not obese, fat is enriched for a unique population of regulatory T cells that affect metabolic parameters. Nat Med. 2009; 15(8):930-9. PMC: 3115752. DOI: 10.1038/nm.2002. View

12.

Koulmanda M, Budo E, Bonner-Weir S, Qipo A, Putheti P, Degauque N . Modification of adverse inflammation is required to cure new-onset type 1 diabetic hosts. Proc Natl Acad Sci U S A. 2007; 104(32):13074-9. PMC: 1941818. DOI: 10.1073/pnas.0705863104. View

13.

Itoh N, Hanafusa T, Miyazaki A, Miyagawa J, Yamagata K, Yamamoto K . Mononuclear cell infiltration and its relation to the expression of major histocompatibility complex antigens and adhesion molecules in pancreas biopsy specimens from newly diagnosed insulin-dependent diabetes mellitus patients. J Clin Invest. 1993; 92(5):2313-22. PMC: 288412. DOI: 10.1172/JCI116835. View

14.

Strom T, Koulmanda M . Cytokine related therapies for autoimmune disease. Curr Opin Immunol. 2008; 20(6):676-81. PMC: 3747560. DOI: 10.1016/j.coi.2008.10.003. View

15.

Zhou X, Bailey-Bucktrout S, Jeker L, Penaranda C, Martinez-Llordella M, Ashby M . Instability of the transcription factor Foxp3 leads to the generation of pathogenic memory T cells in vivo. Nat Immunol. 2009; 10(9):1000-7. PMC: 2729804. DOI: 10.1038/ni.1774. View

16.

Skyler J, Krischer J, Wolfsdorf J, Cowie C, Palmer J, Greenbaum C . Effects of oral insulin in relatives of patients with type 1 diabetes: The Diabetes Prevention Trial--Type 1. Diabetes Care. 2005; 28(5):1068-76. DOI: 10.2337/diacare.28.5.1068. View

17.

Wong F, Wen L, Tang M, Ramanathan M, Visintin I, Daugherty J . Investigation of the role of B-cells in type 1 diabetes in the NOD mouse. Diabetes. 2004; 53(10):2581-7. DOI: 10.2337/diabetes.53.10.2581. View

18.

Lennon G, Bettini M, Burton A, Vincent E, Arnold P, Santamaria P . T cell islet accumulation in type 1 diabetes is a tightly regulated, cell-autonomous event. Immunity. 2009; 31(4):643-53. PMC: 2763021. DOI: 10.1016/j.immuni.2009.07.008. View

19.

Hu C, Rodriguez-Pinto D, Du W, Ahuja A, Henegariu O, Wong F . Treatment with CD20-specific antibody prevents and reverses autoimmune diabetes in mice. J Clin Invest. 2007; 117(12):3857-67. PMC: 2096456. DOI: 10.1172/JCI32405. View

20.

Turley S, Poirot L, Hattori M, Benoist C, Mathis D . Physiological beta cell death triggers priming of self-reactive T cells by dendritic cells in a type-1 diabetes model. J Exp Med. 2003; 198(10):1527-37. PMC: 2194112. DOI: 10.1084/jem.20030966. View